Ultrasound-Guided Vs Non-Guided Prolotherapy for Internal Derangement of Temporomandibular Joint. a Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05627830

Enrollment

Registered

2022-11-28

Start date

2022-11-10

Completion date

2023-10-01

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Disc Displacement, Clicking Tinnitus, Injection Site, Internal Derangement, Masticatory Muscle, Myofascial Pain Syndrome, Pain, Chronic, Prolotherapy, TMJ, TMJ Disc Disorder, Ultrasound Therapy; Complications

Brief summary

Ultrasound Guided Versus Non-Guided Prolotherapy for Treatment of Internal Derangement of Temporomandibular joint. Rationale for conducting the research: The most critical cause for guided prolotherapy is to specify the accurate location of glenoid fossa and the disc space while prolotherapy procedure, and to adjust the needle insertion to according to articular eminence, mandibular condyle, and intra-articular space as anatomical variations. The vibration of ultrasound waves generates a heat so there is a thermal effective for prolotherapy effusion in the TMJ space.

Interventions

PROCEDUREProlotherapy

Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients with TMD - internal derangement with symptomatic clicking pain, according to RDC (Research diagnostic criteria for TMJD) sheet . 2. Muscles spasm causing TMDs. 3. Patients who failed to improve on conservative measures or highly hyperactivity patients. 4. Female and male patients age range from 20 to 60 years old.

Exclusion criteria

1. Patients who refused to be included in the research. 2. Patients with a systemically diseases or inflammation whether local or generalized. 3. Patients with bleeding disorders. 4. Patients with unknown dextrose allergy.

Design outcomes

Primary

Measure	Time frame	Description
visual analogue scale	Change from Baseline VAS at 4 weeks ( lower score means better outcome)	psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026